Dr. Zachary Stephan Zumsteg, MD

Dr. Zumsteg practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Zumsteg's NPI, 1962729004, was assigned on April 29, 2010. Dr. Zumsteg graduated from David Geffen School of Medicine at UCLA in 2010. Dr. Zumsteg holds California license A138272.

Dr. Zumsteg's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Zumsteg's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zumsteg practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Zumsteg's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Zumsteg is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Zumsteg's licenses on file in 2 states: California and New York.

Dmand AI lists bone cancer radiation, head & neck cancer radiation, lymphoma radiation and prostate cancer radiation among the conditions Dr. Zumsteg treats.

CMS data shows 2,130 Medicare services from Dr. Zumsteg across 15 procedure codes in 2024, for 177 Medicare patients. Medicare paid $157,758 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 177 Medicare patients who saw Dr. Zumsteg in 2024. The largest group is 65 to 74, with 85 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 25% are also on Medicaid. Their average risk score is 2.01, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Zumsteg's median patient age at 72, with 21% women.

In 2016, Dr. Zumsteg wrote 110 Medicare Part D claims. Every claim was for a generic drug. They cover 7 drugs, with $5,869 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Zumsteg for performance year 2024, reported as part of a group. Dr. Zumsteg accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Zumsteg as offering telehealth.

Dmand AI links 58 papers to Dr. Zumsteg, published from 2012 to 2025. 2017 was the busiest year, with 7. The most frequent topics are Prostatic Neoplasms, Neoplasm Grading and Radiotherapy Dosage. Dr. Zumsteg has published most often in Eur Urol. Dr. Zumsteg's most frequent co-authors are Allen Szu-Hao Ho, MD, Howard M. Sandler, MD and Yoshiya Yamada, MD.

Dmand AI links Dr. Zumsteg to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Oropharyngeal Neoplasms and Pharyngeal Neoplasms.

CMS Open Payments shows 10 general payments to Dr. Zumsteg from 3 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 84% of the total. EMD Serono, Inc. paid the most, $4,050.

Dr. Zumsteg graduated from David Geffen School of Medicine at UCLA in 2010.

Dr. Zumsteg is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.